Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate,
will serve as Chair of the Scientific Advisory Board
Paris (France), November 28, 2017 – 6:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the establishment of a Scientific Advisory Board comprised of international experts in the fields of DNA Damage Response (DDR), DNA genetics and drug discovery. Professor Tomas Lindahl MD, FRS, FMedSci, a joint recipient of the 2015 Nobel Prize in chemistry for his mechanistic studies of DNA repair, will serve as Chair of the Scientific Advisory Board.
“Scientific evidence has shown that modulating DNA repair activity offers an opportunity to change the course of a disease, notably in cancers,” said Prof. Tomas Lindahl, Emeritus Professor at the Francis Crick Institute (London, UK), joint recipient of the 2015 Nobel Prize in Chemistry and Chair of the Onxeo newly established Scientific Advisory Board. “AsiDNA™ has a new and unique mechanism of action with the potential to bypass cancer cells resistance to treatment while sparing healthy cells. I look forward to working with Onxeo and the distinguished members of the Scientific Advisory Board to further explore the potential of this novel and exciting approach to DNA-targeting.”
“The establishment of this Scientific Advisory Board reflects our commitment to becoming a leading company in the field of DNA-targeting against multiple cancer types for underserved patients,” added Judith Greciet, CEO of Onxeo. “The vision of these renowned experts in the very promising fields of DNA repair, genetics and immune response will considerably reinforce our expertise and support our goal of establishing a new paradigm for cancer treatment.”
The newly established Scientific Advisory Board is a key strategic resource to Onxeo that will provide scientific expertise and guidance to the team as Onxeo advances AsiDNA™ towards clinical development and continues to assess new product development opportunities from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides.
“We are thrilled to welcome this group of international experts to our newly formed Scientific Advisory Board. Their background and experience will be invaluable as we advance AsiDNA™, our DNA break repair inhibitor, into a comprehensive phase I to confirm both its safety profile and unique mechanism of action via systemic administration in man,” added Olivier de Beaumont, Chief Medical Officer of Onxeo.
The inaugural meeting of the Scientific Advisory Board will take place on December 18, 2017 in Paris, France.